INTEGRATED CANNABIS COMPANY, INC.

(formerly CNRP Mining Inc.)

CONDENSED INTERIM FINANCIAL STATEMENTS
THREE AND SIX MONTHS ENDED MAY 31, 2018
(Unaudited – Expressed in Canadian Dollars)

INTEGRATED CANNABIS COMPANY, INC.
(formerly CNRP Mining Inc.)
Condensed Interim Statements of Financial Position
(Unaudited - Expressed in Canadian Dollars)

	As at May 31, 2018	As at November 31, 2017
ASSETS		
Current assets		
Cash	$ 2,702,300	$ -
Subscription receivable	-	330,001
Government HST recoverable	9,175.00	-
Investment (note 1)	1,216,486	-
Prepaid expenses	146,879	-
Total Assets	$ 4,074,840	$ 330,001
EQUITY AND LIABILITIES		
Current liabilities		
Amounts payable and other liabilities (note 3)	$ 28,915	$ 4,850
Loan payable (note 8)	22,859	-
Total liabilities	51,774	4,850
Shareholders' Equity		
Common share capital (note 5)	18,388,583	330,001
Reserve for share-based payments (note 5)	289,722	-
Contributed surplus (note 5)	630,825	-
Deficit	(15,286,064)	(4,850)
Total shareholders' equity	4,023,066	325,151
Total liabilities and shareholders' equity	$ 4,074,840	$ 330,001

Nature of operations (note 1)
Going concern (note 1)

Approved on behalf of the Board of Directors September 28, 2018:

"Sothi Thillairajah" (signed)
Sothi Thillairajah, Director

"Nishal Kumar" (signed)
Nishal Kumar, Director

INTEGRATED CANNABIS COMPANY, INC.
(formerly CNRP Mining Inc.)
Condensed Interim Statements of Loss and Comprehensive Loss
(Unaudited - Expressed in Canadian Dollars)

	Three Months Ended May 31, 2018	Three Months Ended May 31, 2017	Six Months Ended May 31, 2018	Six Months Ended May 31, 2017
Operating Expenses				
Bank Charges	$ 187	$ -	$ 182	$ -
Filing and listing fees	25,820	-	25,820	-
Office and general expenses	21,538	-	21,538	-
Legal and professional fees	24,252	-	24,252	-
Transfer agent fees	5,450	-	5,450	-
Management fees	75,703	-	75,703	-
	(152,950)	-	(152,950)	-
Other				
Listing Fee	(5,114,999)	-	(5,114,999)	-
Net loss and other comprehensive loss	$ (5,267,949)	$ -	$ (5,267,949)	$ -
Basic and diluted net loss per share	(0.32)	-	(0.32)	-
Weighted average number of common shares outstanding	16,716,753	-	16,608,377	-

INTEGRATED CANNABIS COMPANY, INC.
(formerly CNRP Mining Inc.)
Condensed Statements of Cash Flows
(Unaudited - Expressed in Canadian Dollars)

	Six Months Ended May 31, 2018	Six Months Ended May 31, 2017
Operating Activities		
Net loss for the period	(5,267,949)	$ -
Listing Fee	(5,114,999)	-
Net changes in non-cash working capital		
Government HST recoverable	(9,175)	-
Prepaid expenses	(146,879)	-
Accounts payable and accrued liabilities	24,065	-
Net cash used in operating activities	(10,514,937)	-
Investing activities		
Advances for investments	(886,485)	-
RTO Investment	14,080,863	-
Net cash used in investing activities	13,194,378	-
Financing activities	-	-
Loan payable	22,859	-
Net cash provided by financing activities	22,859	-
Net change in cash	2,702,300	-
Cash, beginning of period	-	-
Cash, end of period	$ 2,702,300	$ -

INTEGRATED CANNABIS COMPANY, INC.
(formerly CNRP Mining Inc.)
Condensed Interim Statements of Changes in Equity
(Unaudited - Expressed in Canadian Dollars)

	Common Share Capital					
	Number of Shares	**Amount**	**Reserves for Share-based Payments**	**Contributed Surplus**	**Deficit**	**TOTAL**
Balance, July 20, 2017	**1**	**$ 1**	**$ -**	**$ -**	**$ -**	**$ 1**
Shares issued	16,500,000	330,000	-	-	-	**330,000**
Loss for the period	-	-	-	-	(4,850)	**(4,850)**
Balance at November 30, 2017	**16,500,001**	**$ 330,001**	**$ -**	**$ -**	**$ (4,850)**	**$ 325,151**
Reverse takeover (note 2)						
Elimination entry	(16,500,000)	(330,001)				**(330,001)**
Recapitalization	17,857,786	12,943,583	289,722	630,825.00	(10,013,265)	**3,850,865**
Acquisition shares	16,500,000	4,950,000				**4,950,000**
Shares issued as finder's fee	1,650,000	495,000				**495,000**
Loss for the period					(5,267,949)	**(5,267,949)**
Balance at May 31, 2018	**36,007,787**	**$18,388,583**	**$ 289,722**	**$ 630,825**	**$ (15,286,064)**	**$4,023,066**

The notes to the condensed interim financial statements are an integral part of these statements

1. NATURE OF BUSINESS AND CONTINUING OPERATIONS

Integrated Cannabis Company Inc. (formerly 1127466 B.C. Ltd.) ("the Company") was incorporated pursuant to the provisions of the Business Corporations Act of British Columbia on July 20, 2017. The Company's registered head office address is 905 – 1600M Beach Avenue, Vancouver, British Columbia.

The Company through its wholly owned subsidiary XSPRAYS Industries Inc. owns the worldwide exclusive rights to market and sell as dietary supplements for nonmedical use only cannabinoid and cannabis-infused sprays. In addition, the company has a non-exclusive license to market and sell as dietary supplements for non-medical use of non-cannabis infused sprays.

The Company does not generate revenue from operations. The Company incurred a net loss of $5,267,949 (2017 - $4,850) from the six months ended May 31, 2018, and, as of that date, the Company's deficit was $15,286,064 (2017 - $4,850). The Company expects to incur further losses in the development of its business, all of which casts significant doubt about the Company's ability to continue as a going concern. The Company's ability to continue as a going concern is dependent upon the ability to find, acquire and develop various businesses with growth potential, its ability to obtain the necessary financing to carry out this strategy. These consolidated financial statements have been prepared on a going concern basis, which presumes realization of assets and discharge of liabilities in the normal course of business for the foreseeable future. These consolidated financial statements do not include any adjustments to the amounts and classification of assets and liabilities that might be necessary should the Company be unable to continue in business. Such adjustments could be material.

Reverse Takeover

On October 25, 2017, the Company and 1127466 B.C. Ltd. signed a share exchange agreement whereby the Company would acquire all of the issued and outstanding shares of the 1127466 B.C. Ltd. which holds, through a wholly owned subsidiary, a world-wide, exclusive license for X-SPRAYS – a brand of life-enhancement products administered via an optimal oral spray delivery system. Pursuant to the terms of the agreement, Integrated Cannabis issued an aggregate of 16,500,000 common shares in the capital of the Company (the "Payment Shares") at a deemed price of CAD$0.30 per Payment Share. Also, as part of the transaction the Company also issued a finder's fee of 1,650,000 common shares in the capital of the Company at a deemed price of CAD$0.30 per share.

In accordance with IFRS 3, Business Combinations, the substance of the transaction was an acquisition of an operating company with no developed business. The transaction does not constitute a business combination since Target does not meet the definition of a business under the standard. As a result, under IFRS the transaction is accounted for as a reverse asset acquisition and takeover ("RTO").

As 1127466 B.C. Ltd. is deemed to be the accounting acquirer for accounting purposes, its assets and liabilities and operations since incorporation on July 20, 2017 are included in the condensed consolidated interim financial statements at their historical carrying value. The condensed consolidated interim financial statements are a continuation of 1127466 B.C. Ltd. in accordance with IFRS 3, Business Combinations.

2. BASIS OF PRESENTATION AND STATEMENT OF COMPLIANCE

These consolidated financial statements are prepared by the Company in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB"). These consolidated financial statements have been prepared using the accrual basis of accounting, except for cash flow information. Furthermore, these consolidated financial statements are presented in Canadian dollars which is the functional currency of the Company.

The preparation of consolidated financial statements in conformity with IFRS requires the Company's

2. BASIS OF PRESENTATION AND STATEMENT OF COMPLIANCE (continued)

management to make judgments, estimates and assumptions about future events that affect the amounts reported in the consolidated financial statements and related notes to the financial statements. Although these estimates are based on management's best knowledge of the amount, event or actions, actual results may differ from those estimates.

These consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, XSPRAYS Industries Inc. All inter-company transactions and balances have been eliminated in the consolidated financial statement presentation.

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

(a) Cash and cash equivalents

Cash in the statements of financial position is comprised of cash held at a major financial institution.

(b) Financial instruments

Financial assets

The Company classifies its financial assets into one of the following categories, depending on the purpose for which the asset was acquired. The Company's accounting policy for each category is as follows:

(i) Fair value through profit or loss - This category comprises derivatives, or assets acquired principally for the purpose of being resold in the near term. They are carried on the statement of financial position at fair value with changes in fair value recognized in the statement of comprehensive loss. The Company has classified cash as fair value through profit or loss.

(ii) Loans and receivables - These assets are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market. They are carried at cost less any provision for impairment. Individually significant receivables are considered for impairment when they are past due or when other objective evidence is received that a specific counterparty will default. The Company has classified loan receivables as loans and receivables.

(iii) Held-to-maturity investments – These assets are recognized on a trade-date basis and are initially measured at fair value, including transaction costs. The Company does not have any assets classified as HTM investments.

(iv) Available-for-sale - Non-derivative financial assets not included in the above categories are classified as available-for-sale. They are carried at fair value with changes in fair value recognized directly in equity. Where a decline in the fair value of an available-for-sale financial asset constitutes objective evidence of impairment, the amount of the loss is removed from equity and recognized in the statement of comprehensive loss. The Company does not have any assets classified as available-for-sale assets.

All financial assets except for those at fair value through profit or loss are subject to review for impairment at least at each reporting date. Financial assets are impaired when there is any objective evidence that a financial asset or a group of financial assets is impaired. Different criteria to determine impairment are applied for each category of financial assets described

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

above.

Financial liabilities

The Company classifies its financial liabilities into one of two categories, depending on the purpose for which the asset was acquired. The Company's accounting policy for each category is as follows:

(i) Fair value through profit or loss - This category comprises derivatives, or liabilities acquired or incurred principally for the purpose of selling or repurchasing in the near term. They are carried on the statement of financial position at fair value with changes in fair value recognized in the statement of comprehensive loss.

(ii) Other financial liabilities - This category includes accounts payables and accrued liabilities, all of which are recognized at amortized cost.

(b) Income taxes

Income tax expense comprises current and deferred tax. Income tax is recognized in profit or loss except to the extent that it relates to items recognized directly in equity. Current tax expense is the expected tax payable on taxable income for the year, using tax rates enacted or substantively enacted at period end, adjusted for amendments to tax payable with regards to previous years.

(c) Income taxes (continued)

Deferred tax is recorded using the liability method, providing for temporary differences, between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. Temporary differences are not provided for relating to goodwill not deductible for tax purposes, the initial recognition of assets or liabilities that affect neither accounting or taxable loss, and differences relating to investments in subsidiaries to the extent that they will probably not reverse in the foreseeable future. The amount of deferred tax provided is based on the expected manner of realization or settlement of the carrying amount of assets and liabilities, using tax rates enacted or substantively enacted at the end of the reporting period. A deferred tax asset is recognized only to the extent that it is probable that future taxable profits will be available against which the asset can be utilized.

(d) Loss per share

The Company presents basic and diluted loss per share data for its common shares, calculated by dividing the loss attributable to common shareholders of the Company by the weighted average number of common shares outstanding during the period. Diluted loss per share does not adjust the loss attributable to common shareholders or the weighted average number of common shares outstanding when the effect is anti-dilutive.

(e) Significant accounting judgments and estimates

The preparation of consolidated financial statements in conformity with IFRS requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported revenues and expenses during the year. Although management uses historical experience and its best knowledge of the amount, events or actions to form the basis for

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

judgments and estimates, actual results may differ from these estimates. The most significant accounts that require estimates as the basis for determining the stated amounts include recognition of deferred income tax amounts.

Critical judgments exercised in applying accounting policies that have the most significant effect on the amounts recognized in the consolidated financial statements are as follows:

Determination of functional currency

The Company determines the functional currency through an analysis of several indicators such as expenses and cash flow, financing activities, retention of operating cash flows, and frequency of transactions with the reporting entity.

Income taxes

In assessing the probability of realizing income tax assets, management makes estimates related to expectations of future taxable income, applicable tax opportunities, expected timing of reversals of existing temporary differences and the likelihood that tax positions taken will be sustained upon examination by applicable tax authorities. In making its assessments, management gives additional weight to positive and negative evidence that can be objectively verified.

(f) Effective for annual periods beginning on or after December 1, 2017:

IFRS 9 – Financial Instruments (“IFRS 9”) was issued by the IASB in November 2009 with additions in October 2010 and May 2013 and will replace IAS 39 Financial Instruments: Recognition and Measurement (“IAS 39”). IFRS 9 uses a single approach to determine whether a financial asset is measured at amortized cost or fair value, replacing the multiple rules in IAS 39. The approach in IFRS 9 is based on how an entity manages its financial instruments in the context of its business model and the contractual cash flow characteristics of the financial assets. Most of the requirements in IAS 39 for classification and measurement of financial liabilities were carried forward unchanged to IFRS 9, except that an entity choosing to measure a financial liability at fair value will present the portion of any change in its fair value due to changes in the entity’s own credit risk in other comprehensive income, rather than within profit or loss. The new standard also requires a single impairment method to be used, replacing the multiple impairment methods in IAS 39. IFRS 9 is effective for annual periods beginning on or after January 1, 2018. Earlier adoption is permitted.

4. ACQUISITION OF EXCLUSIVE RIGHTS TO SPRAY LABS, LLC

During the period ended November 30, 2017, the Company entered into an asset purchase agreement with Spray Labs, LLC to purchase the worldwide, exclusive rights to market and sell as dietary supplements for non-medical use only the cannabinoid and cannabis-infused sprays that have been, and will in the future be, developed by SPRAY LABS, LLC., including, but not limited to a THC product that is currently being developed. In addition, SPRAY LABS, LLC grants a non-exclusive license to market and sell as dietary supplements for non-medical use only four (4) “non-cannabis infused” sprays under the X-Sprays label. This purchase agreement does not cover: a: any products, cannabis-infused or otherwise, that Spray Labs, LLC develops for medicinal and therapeutic use and for which FDA (or foreign equivalent) approval is sought, and b: any patented formulations or the rights granted by any patents awarded to SPRAY LABS, LLC.

5. SHARE CAPITAL

a) Authorized

Unlimited number of common shares without par value and unlimited number of special shares, issuable in series.

b) Issued and outstanding

On July 20, 2017, the date of incorporation, 1 common share without par value at $0.001 per common share was issued as subscription receivable. The full amount was received subsequent to the period ended November 30, 2017 (See Note 10).

On November 30, 2017, 16,500,000 common shares without par value at $0.02 per common share were issued as subscription receivables. The full amount was received subsequent to the period ended November 30, 2017.

On May 31, 2018, the Company completed its reverse takeover resulting in a total of 36,007,787 common shares outstanding.

c) Warrants

In conjunction with the reverse takeover, the Company has 1,948,957 warrants outstanding as of May 31, 2018.

d) Contributed Surplus

Contributed surplus includes the accumulated fair value of share-based compensation and warrants transferred from share-based payment reserve and warrant reserve upon cancellation or expiry of the stock options and warrants.

6. MANAGEMENT OF CAPITAL

The Company considers its capital structure to include the components of shareholders' equity. Management's objective is to ensure that there is sufficient capital to minimize liquidity risk and to continue as a going concern. Although the Company has been successful in the past in obtaining financing, there can be no assurance that the Company will be able to obtain adequate financing in the future, or that the terms of such financings will be favorable. The Company is not subject to any externally imposed capital requirements.

7. FINANCIAL INSTRUMENTS

Fair Value

The Company's financial instruments consist of amounts receivable. The fair values of financial instruments other than cash approximate their carrying values because of their current nature.

Credit Risk

The Company's cash is largely held in large Canadian financial institutions. The Company does not have any asset-backed commercial paper. The Company maintains cash deposits with Schedule A financial institution, which from time to time may exceed federally insured limits. The Company has not experienced any significant credit losses and believes it is not exposed to any significant credit risk.

Liquidity Risk

The Company's ability to continue as a going concern is dependent on management's ability to raise required funding through future equity issuances and through short-term borrowing. The Company manages its liquidity risk by forecasting cash flows from operations and anticipating any investing and financing activities. Management and the Board of Directors are actively involved in the review,

7. FINANCIAL INSTRUMENTS (continued)

planning and approval of significant expenditures and commitments.

Foreign Exchange Risk

The Company's functional and reporting currency is the Canadian dollar and major purchases are transacted in Canadian dollars. As a result, the Company's exposure to foreign currency risk is minimal.

Interest Rate Risk

Interest rate risk is the risk the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. Financial assets and liabilities with variable interest rates expose the Company to cash flow interest rate risk. The Company does not hold any financial liabilities with variable interest rates. The Company does maintain bank accounts which earn interest at variable rates but it does not believe it is currently subject to any significant interest rate risk.

8. LOAN PAYABLE

During the period ended May 30, 2018 the Company received a loan from a non-related party in the amount of $22,859. This loan was non-interest bearing, unsecured, and due on demand.

9. SUBSEQUENT EVENTS

In connection with the closing of the acquisition, the Company announces that certain of its previous directors and officers have resigned. The Company announces that the board of directors now consists of John Knapp, Clive Spray, Sothi Thillairajah and Nishal Kumar. Management now consists of John Knapp (CEO), Clive Spray (Chief Scientific and Operations Officer) and Eugene Beukman (CFO and Corporate Secretary).

On June 7, 2018 the Company announced that its common shares would resume trading on the CSE on June 8, 2018 under the symbol "ICAN".

On September 20, the Company announced the completion of a Letter of Intent (LOI) to distribute X-SPRAYS™ products throughout the clinics and doctors' offices of Empower Clinics Inc., a leading owner and operator of medical cannabis and wellness clinics in the United States (US).

On September 27, 2018, the Company announce the completion of a Letter Agreement to collaborate on X-SPRAYS™ products for the Canadian market with GTEC Holdings Ltd., a Canadian License Producer under Health Canada's Access to Cannabis for Medical Purposes Regulations (ACMPR).